Wolverine Trading, LLC Uni Qure N.V. Call Options Transaction History

Wolverine Trading, LLC

16 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$4.39 - $5.43 $6,584 - $8,145	-1,500 Reduced 4.35%	33,000 $147,000
Q1 2024 May 15, 2024	BUY	$4.82 - $6.93 $31,330 - $45,045	6,500 Added 23.21%	34,500 $179,000
Q4 2023 Feb 14, 2024	BUY	$5.63 - $8.27 $11,823 - $17,367	2,100 Added 8.11%	28,000 $189,000
Q3 2023 Nov 15, 2023	BUY	$6.71 - $11.83 $67,771 - $119,483	10,100 Added 63.92%	25,900 $173,000
Q2 2023 Aug 23, 2023	BUY	$11.12 - $22.2 $175,696 - $350,760	15,800 New	15,800 $181,000
Q3 2022 Nov 14, 2022	SELL	$16.98 - $25.54 $18,678 - $28,094	-1,100 Reduced 6.21%	16,600 $297,000
Q2 2022 Aug 15, 2022	BUY	$13.15 - $20.45 $11,835 - $18,405	900 Added 5.36%	17,700 $327,000
Q1 2022 May 16, 2022	BUY	$14.54 - $21.5 $244,272 - $361,200	16,800 New	16,800 $300,000
Q4 2021 Feb 14, 2022	SELL	$20.24 - $36.01 $208,471 - $370,903	-10,300 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$26.01 - $38.22 $80,631 - $118,482	3,100 Added 43.06%	10,300 $325,000
Q2 2021 Aug 06, 2021	SELL	$29.97 - $37.17 $152,847 - $189,567	-5,100 Reduced 41.46%	7,200 $225,000
Q1 2021 May 14, 2021	BUY	$29.24 - $42.03 $122,808 - $176,526	4,200 Added 51.85%	12,300 $409,000
Q4 2020 Feb 12, 2021	SELL	$35.35 - $50.67 $49,490 - $70,938	-1,400 Reduced 14.74%	8,100 $301,000
Q3 2020 Nov 13, 2020	BUY	$35.98 - $47.66 $133,126 - $176,342	3,700 Added 63.79%	9,500 $342,000
Q2 2020 Aug 13, 2020	BUY	$45.06 - $67.74 $58,578 - $88,062	1,300 Added 28.89%	5,800 $265,000
Q1 2020 May 11, 2020	BUY	$40.01 - $73.97 $180,045 - $332,865	4,500 New	4,500 $203,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.